JeanMarie Guenot is the founder, President, and Chief Executive Officer for pharmaceutical company Amphivena Therapeutics. Amphivena Therapeutics, based in San Francisco, develops therapies for the treatment of cancer. In 2016 one of their products was accepted by the U.S. Food and Drug Administration as an investigational new drug. This acceptance allowed the company to start Phase 1 of the drug which involves a dose escalation and expansion trial in patients. The drug, AMV564, uses an antibody to recruit T-cells to eliminate cancer cells in patients suffering from acute myeloid leukemia.
Guenot earned her MBA from The Wharton School at the University of Pennsylvania. She earned her Ph.D. from the University of Califonia, San Francisco, in 1993. She started her professional career at Hoffman-La Roche where she was a Team Leader and Principal Scientist in Preclinical Research and Development. In her career she has also worked as an Associate in Life Sciences at Atlas Ventures as well as a Vice President at PDL BioPharma. She founded her first company, Guenot, LLC, in 2008 and served as its Managing Partner. Her second company, founded in 2009, was SKS Ocular, LLC where she served as a Partner. SKS Ocular was focused on dry AMD which is a technology that delivers drugs to treat glaucoma, ocular inflammation, and macular degeneration. Find her on Facebook here: https://www.facebook.com/jeanmarie.guenot.9
Through working on both the science side and business side in the pharmaceuticals JeanMarie Guenot has worked all facets of the field. She is noted for her deep knowledge research and development of groundbreaking cancer therapies. She is also noted for her experience in neurology, cardiovascular diseases, optometry, oncology, and autoimmune diseases. She has also developed a wide range of business skills including leadership, business development, alliance management, and skillfully raising venture capital.
In her career JeanMarie Guenot has won a number of awards. Among these is the Deal Of Distinction Award, given by the Licensing Executive Society, in 2006. In 2005 she won the BioBusiness Network Innovative Bio-Partnering award.